| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_92c919237cd10f437e2e29529230052a |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2121-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-54 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-165
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-337
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0019
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-3955
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-395
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-5169 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-165
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-51
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-337 |
| filingDate |
2016-07-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5964017d8f09f95d53d2b16079badd2f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ddd76d3620d37494a2d71bffe235a094 |
| publicationDate |
2017-04-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2017105951-A1 |
| titleOfInvention |
Combination therapy with thiocolchicine derivatives |
| abstract |
The present invention provides combination therapy methods of treating a proliferative disease (such as cancer) comprising administering to an individual an effective amount of a colchicine or thiocolchicine dimer and an anti-VEGF antibody. The method may further comprise administering an effective amount of a taxane. The colchicine or thiocolchicine dimer and the taxane (such as paclitaxel) may be present in the form of nanoparticles, such as nanoparticles comprising the drug and a carrier protein such as albumin. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10328031-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9962373-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11497737-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9884013-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10744110-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10206887-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11320416-B1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10900951-B1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10258565-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10705070-B1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10973806-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10527604-B1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10682420-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10076501-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10660965-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10413531-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10555912-B2 |
| priorityDate |
2009-03-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |